Aktuellt
SENASTE
BB Biotech’s shares closed at CHF 37.7 on 23 January 2025 versus a net asset value per share of CHF 45.4 (Bloomberg estimate), reflecting a 17.0% discount. The average NAV discount LTM has been 7.1% and the shares have traded on an average 9.7% premium over the last five years). The top holding company Intra Cellular Therapies was acquired by Johnson & Johnson at a 40% premium.
LÄS MER
